Presenter: Eunice S. Wang, M.D. A post-hoc analysis of the pivotal cohort from the Phase 1/2 study evaluated outcomes in patients with R/R mIDH1 AML who received olutasidenib after either 1-2 or ...

Title: Efficacy and Safety of Pralsetinib in Patients with Advanced RET-fusion-positive NSCLC: Final Data from the Phase 1/2 ARROW Study Presenter: Eunice S. Wang, M.D. A post-hoc analysis of ...

As an analyst tracking small-cap biotech names, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has always been one of my favorites, thanks to the company’s evolution from a TAVALISSE-centric company ...

Rigel Pharmaceuticals Inc. (RIGL) reported robust financial results for Q1 2025, with total revenue reaching $53.3 million, marking a 68% year-over-year increase. The company’s net income was $ ...

Rigel Pharmaceuticals (RIGL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

SOUTH SAN FRANCISCO, Calif., April 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals ...

Rigel Pharmaceuticals (NASDAQ:RIGL – Free Report) had its target price increased by Citigroup from $49.00 to $55.00 in a research report report published on Thursday morning,Benzinga reports.

LAMAR COUNTY, Miss. (WDAM) - Lamar County Sheriff Danny Rigel has documented 40 years of his law enforcement career in a binder. Most officers would use crime reports or newspaper clippings Rigel ...

Rigel Pharmaceuticals (RIGL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today ...